Oral oncology · 2026
The impact of regional lymph node depletion on response to anti-PD-1 therapy in recurrent and metastatic head and neck squamous cell carcinoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Smith Joshua D, Santiago Riley, Doerfler Rose, Harris Micah K, Contrera Kevin J, Chinn Steven B, Bao Riyue, Kelly Zahra R, Mowery Yvonne M, Wilke Christopher T, Skinner Heath D, Zevallos Jose P, Zandberg Dan P, Spector Matthew E
Аннотация
OBJECTIVE: Cervical lymphadenectomy remains a central component of definitive treatment for primary head and neck squamous cell carcinoma (HNSCC). However, the impact of previous lymphadenectomy, and extent thereof, on anti-PD-1 response in patients who develop recurrent/metastatic (R/M) disease after definitive treatment remains unknown. Here, we evaluated the hypothesis that history of regional lymph node depletion is associated with decreased efficacy of anti-PD-1 therapy in patients who suffer R/M HNSCC after definitive treatment.
MATERIALS AND METHODS: This was a single-institution, retrospective cohort study of 97 patients treated with anti-PD-1 mAb for R/M HNSCC. Impact of regional lymph node (LN) depletion (i.e., bilateral lymphadenectomy, five or more levels dissected, and/or 18 or more lymph nodes excised at any time prior to anti-PD-1 therapy) was examined as a predictor of R/M HNSCC disease control rate (DCR: SD, PR, or CR), progression-free survival (PFS) and overall survival (OS) with Kaplan-Meier method and multivariate models.
RESULTS: Ninety-seven patients (median age 62 years, 72 % male, 76 % p16- HNSCC); 48 (50 %) patients had a history of regional LN depletion prior to anti-PD-1 therapy. Regional LN depletion was significantly associated with poorer DCR and PFS after anti-PD-1 alone and controlling for history of platinum chemotherapy failure (OR: 0.12 [0.02 - 0.66], p = 0.008 for DCR, HR: 1.89 [1.04 - 3.38], p = 0.04 for PFS).
CONCLUSIONS: In this retrospective, single-institution study of patients with R/M HNSCC, regional LN depletion was independently associated with lower DCR and PFS after anti-PD-1 therapy.
MATERIALS AND METHODS: This was a single-institution, retrospective cohort study of 97 patients treated with anti-PD-1 mAb for R/M HNSCC. Impact of regional lymph node (LN) depletion (i.e., bilateral lymphadenectomy, five or more levels dissected, and/or 18 or more lymph nodes excised at any time prior to anti-PD-1 therapy) was examined as a predictor of R/M HNSCC disease control rate (DCR: SD, PR, or CR), progression-free survival (PFS) and overall survival (OS) with Kaplan-Meier method and multivariate models.
RESULTS: Ninety-seven patients (median age 62 years, 72 % male, 76 % p16- HNSCC); 48 (50 %) patients had a history of regional LN depletion prior to anti-PD-1 therapy. Regional LN depletion was significantly associated with poorer DCR and PFS after anti-PD-1 alone and controlling for history of platinum chemotherapy failure (OR: 0.12 [0.02 - 0.66], p = 0.008 for DCR, HR: 1.89 [1.04 - 3.38], p = 0.04 for PFS).
CONCLUSIONS: In this retrospective, single-institution study of patients with R/M HNSCC, regional LN depletion was independently associated with lower DCR and PFS after anti-PD-1 therapy.